
-
Heat humble Celtics for sixth straight win, Thunder roll on
-
Trump escalates trade war with sweeping global tariffs
-
Japan says US tariffs 'extremely regrettable', may break WTO rules
-
South Koreans anxious, angry as court to rule on impeached president
-
Juve at in-form Roma with Champions League in the balance
-
Injuries put undermanned Bayern's title bid to the test
-
Ovechkin scores 892nd goal -- three away from Gretzky's NHL record
-
Australian former rugby star Petaia signs for NFL's Chargers
-
China says opposes new US tariffs, vows 'countermeasures'
-
Athletics world watching as 'Grand Slam Track' prepares for launch
-
Heat humble Celtics for sixth straight win, Cavs top Knicks
-
Quake-hit Myanmar's junta chief to head to Bangkok summit
-
New Spielberg, Nolan films teased at CinemaCon
-
Shaken NATO allies to meet Trump's top diplomat
-
Israel's Netanyahu arrives in Hungary, defying ICC warrant
-
Shiny and deadly, unexploded munitions a threat to Gaza children
-
Stocks tank, havens rally as Trump tariffs fan trade war
-
Altomare hangs on to tie defending champ Korda at LPGA Match Play
-
Paraguay gold rush leaves tea producers bitter
-
Health concerns swirl as Bolivian city drowns in rubbish
-
Syria says deadly Israeli strikes a 'blatant violation'
-
Financial markets tumble after Trump tariff announcement
-
Starbucks faces new hot spill lawsuits weeks after $50mn ruling
-
Europe riled, but plans cool-headed response to Trump's tariffs
-
'Shenmue' voted most influential video game ever in UK poll
-
New coal capacity hit 20-year low in 2024: report
-
Revealed: Why monkeys are better at yodelling than humans
-
Key details on Trump's market-shaking tariffs
-
'A little tough love': Top quotes from Trump tariff talk
-
US business groups voice dismay at Trump's new tariffs
-
Grealish dedicates Man City goal to late brother
-
US tariffs take aim everywhere, including uninhabited islands
-
Trump sparks trade war with sweeping global tariffs
-
Israeli strikes hit Damascus, central Syria; monitor says 4 dead
-
Slot 'hates' offside rule that gave Liverpool win over Everton
-
US stocks end up, but volatility ahead after latest Trump tariffs
-
Barca oust Atletico to set up Clasico Copa del Rey final
-
Mourinho grabs Galatasaray coach's face after losing Istanbul derby
-
Grealish strikes early as Man City move up to fourth in Premier League
-
Reims edge out fourth-tier Cannes to set up PSG French Cup final
-
Liverpool beat Everton as title looms, Man City win without Haaland
-
Jota wins bad-tempered derby as Liverpool move 12 points clear
-
Inter and Milan level in derby Italian Cup semi
-
Stuttgart beat Leipzig to reach German Cup final
-
Trump unveils sweeping global tariffs
-
Italian director Nanni Moretti in hospital after heart attack: media
-
LIV Golf stars playing at Doral with Masters on their minds
-
Trump unveils sweeping 'Liberation Day' tariffs
-
Most deadly 2024 hurricane names retired from use: UN agency
-
Boeing chief reports progress to Senate panel after 'serious missteps'

US approves new drug to treat Alzheimer's
The US Food and Drug Administration on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in the early stages of Alzheimer's disease.
The FDA approval of the drug, Leqembi, also known as lecanemab, came just days after the agency was harshly criticized in a congressional report for its green-lighting of another Alzheimer's drug, Aduhelm.
And it was granted despite trial results showing the monoclonal antibody treatment carries risks of brain swelling and bleeding.
Both drugs were approved by the FDA through an accelerated process that allows the US regulatory agency to fast-track approval of drugs for serious conditions where there is an unmet medical need.
Leqembi and Aduhelm, which were both jointly developed by Japan's Eisai and Biogen of the United States, "represent an important advancement in the ongoing fight to effectively treat Alzheimer's disease," the FDA said in a statement.
"Alzheimer's disease immeasurably incapacitates the lives of those who suffer from it and has devastating effects on their loved ones," Billy Dunn of the FDA's Center for Drug Evaluation and Research said in a statement.
Leqembi is "the latest therapy to target and affect the underlying disease process of Alzheimer's, instead of only treating the symptoms of the disease," Dunn said.
Preliminary data from a trial of Leqembi was released in September and found it slowed cognitive decline in Alzheimer's patients by 27 percent.
The phase three trial involved nearly 1,800 people, divided between those given the drug and given a placebo, and ran over 18 months.
The complete trial data, published in the New England Journal of Medicine, fleshed out the findings but also raised concern about the incidence of "adverse effects" including brain bleeds and swelling.
The results showed that 17.3 percent of patients administered the drug experienced brain bleeds, compared with nine percent of those receiving a placebo.
And 12.6 percent of those taking the drug experienced brain swelling, compared with just 1.7 percent of those in the placebo group.
Deaths were reported at approximately the same rate in both arms of the trial of the drug.
In Alzheimer's disease, two key proteins, tau and amyloid beta, build up into tangles and plaques, known together as aggregates, which cause brain cells to die and lead to brain shrinkage.
Leqembi works by targeting amyloid.
Biogen and Eisai previously brought Aduhelm to market, but there was significant controversy over whether it worked, and its approval in 2021 led to three high-level resignations in the FDA.
An 18-month US congressional investigation said the approval process for Aduhelm was "rife with irregularities" and criticized both the agency and Biogen.
The Cambridge, Massachusetts-based Biogen set an "unjustifiably high price" for Aduhelm of $56,000 a year, the congressional report said.
Eisai said Leqembi would be priced initially at $26,500 per year.
A.Malone--AMWN